IMRX | Immuneering Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8200 - 3.83
52 Week Range	1.0000 - 9.00
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	64,135,415
Average Volume	4,034,858
Shares Outstanding	29,653,400
Market Cap	85,105,258
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-30

Valuation
Profitability
Growth
Health
P/E Ratio	-1.51
Forward P/E Ratio	N/A
EPS	-1.90
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	66
Country	USA
Website	IMRX

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

IMRX's peers: GNLX, THRX, PMVP, CGEM, ELVN, LRMR, CNTA, CELC, IKNA, REPL, NVCT, LYRA, KRON, GOSS, GLUE, NAMS, IVA, CMPX, MOR, MRNS, ORIC, PRAX, BLTE

*Chart delayed

Analyzing fundamentals for IMRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IMRX Fundamentals page.

Watching at IMRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMRX Technicals page.